Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin

Biochemistry

Volumn 35, Issue 24, 1996, Pages 8058-8067

  Markland, William ^a,b   Ley, Arthur Charles ^a   Ladner, Robert Charles ^a  

^a Protein Engineering Corporation   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BINDING PROTEIN; KALLIKREIN; PLASMIN; PROTEINASE; PROTEINASE INHIBITOR; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; TRYPSIN;

AMINO ACID SEQUENCE; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; ENZYME ACTIVE SITE; FIBRINOLYSIS; GENE LIBRARY; GENETIC ENGINEERING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY;

AMINO ACID SEQUENCE; APROTININ; BACTERIOPHAGE M13; BINDING SITES; CLONING, MOLECULAR; DRUG STABILITY; GENE LIBRARY; HUMANS; KALLIKREINS; KINETICS; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; PICHIA; SACCHAROMYCES CEREVISIAE; SEQUENCE HOMOLOGY, AMINO ACID; SERINE PROTEINASE INHIBITORS; THERMODYNAMICS; THROMBIN; VARIATION (GENETICS);

EID: 0029894775     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi952629y     Document Type: Article

References (31)

1. Ascenzi, P., Coletta, M., Amiconi, G., de Cristofaro, R., Molognesi, M., Guarneri, M., & Menegatti, E. (1988) Binding of the Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz) to Human α-, β-, and γ-Thrombin: A Kinetic and Thermodynamic Study, Biochim. Biophys. Acta 956, 156-161.
2. 52]Aprotinin, Biol. Chem. Hoppe-Seyler 369 (Suppl.), 27-35.
3. Barr, K. A., Hopkins, S. A., & Sreekrishna, K. (1992) Protocol for Efficient Secretion of HSA Developed from Pichia pastoris, Pharm. Eng. 12, 48-51.
4. Berndt, K. D., Beunink, J., Schroeder, W., & Wuethrich, K. (1993) Designed Replacement of an Internal Hydration Water Molecule in BPTI: Structural and Functional Implications of a Glycine-to-Serine Mutation, Biochemistry 32, 4564-4570.
5. Bhoola, K. D., Figueroa, C. D., & Worthy, K. (1992a) Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases, Pharmacol. Rev. 44, 1-80.
6. Bhoola, K. D., Elson, C. J., & Dieppe, P. A. (1992b) Kinins - Key Mediators in Inflammatory Arthritis? Br. J. Rheumatol. 31, 509-518.
7. Bidstrup, B. P., Royston, D., Sapsford, R. N., & Taylor, K. M. (1989) Reduction in Blood Loss and Blood Use after Cardiopulmonary Bypass High Dose Aprotinin (Trasylol), J. Thorac. Cardiovasc. Surg. 97, 364-372.
8. Bode, W., Mayr, L, Baumann, U., Huber R., Stone, S. R., & Hofsteenge, J. (1989) The Refined 1.9 Å Crystal Structure of Human α-Thrombin: Interaction with D-Phe-Pro-Arg Chloromethyl Ketone and Significance of the Tyr-Pro-Pro-Trp Insertion Segment, EMBO J. 8, 3467-3475.
9. Clackson, T., & Wells, J. A. (1995) A Hot Spot of Binding Energy in a Hormone-Receptor Interface, Science 267, 383-386.
10. Cumming, A. D. (1994) Acute Renal Failure and Sepsis: Therapeutic Approaches, Nephrol., Dial., Transplant. 9 (Suppl. 4), 159-163.
11. a. I. Potent Inhibitors Selected from Libraries by Phage Display, J. Biol. Chem. 269, 22129-22136.
12. a. II. Potent and Specific Inhibitors by Competitive Phage Selection, J. Biol. Chem. 269, 22137-22144.
13. Dennis, M. S., Herzka, A., & Lazarus, R. A. (1995) Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display, J. Biol. Chem. 270, 25411-25417.
14. Fritz, H., & Wunderer, G. (1983) Biochemistry and Applications of Aprotinin: The Kallikrein Inhibitor from Bovine Organs, Arzneim.-Forsch. 33, 479-494.
15. Ladner, R. C., & Markland, W. (1995) Kallikrein Inhibiting Proteins Comprising a Kunitz Domain Homologous to Bovine Pancreatic Trypsin Inhibitoi - Useful for Preventing or Treating Disorders Attributed to Excessive Kallikrein Activity, e.g. in Hereditary Angioedema, Pat. Appl. WO95/21601.
16. Le Bonniec, B. F., Guinto, E. R., & Esmon, C. T. (1992) Interactions of Thrombin des-ETW with Antithrombin III, the Kunitz Inhibitor, Thrombomodulin, and Protein C, J. Biol. Chem. 267, 19341-19348.
17. Le Bonniec, B. F., Guinto, E. R., MacGillivray, R. T. A., Stone, S. R., & Esmon, C. T. (1993) The Role of Thrombin's Tyr-Pro-Pro-Trp Motif in the Interaction with Fibrinogen, Thrombo-modulin, Protein C, Antithrombin III, and the Kunitz Inhibitor, J. Biol. Chem. 268, 19055-19061.
18. Markland, W., Roberts, B. L., Saxena, M. J., Guterman, S. K., & Ladner, R. C. (1991) Design, Construction and Function of a Multicopy Display Vector Using Fusions to the Major Coat Protein of Bacteriophage M13, Gene 109, 13-19.
19. Markland, W., Ley, A. C., Lee, S. W., & Ladner, R. C. (1996) Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. I. Plasmin, Biochemistry 35, 8045-8057 (preceding paper).
20. Olson, S. T., Sheffer, R., & Shore, J. D. (1992) Parallel Procoagulant and Anticoagulant Pathways for High Molecular Weight Kininogen Coagulant Function, Agents Actions Suppl. 38, 241-248.
21. Putterman, C. (1989) Letter: Aprotinin Therapy in Septic Shock, Acta Chir. Scand. 155, 367.
22. Roberts, B. L., Markland, W., Ley, A. C., Kent, R. B., White, D. W., Guterman, S. K., & Ladner, R. C. (1992a) Directed Evolution of a Protein: Selection of Potent Neutrophil Elastase Inhibitors Displayed on M13 Fusion Phage, Proc. Natl. Acad. Sci. U.S.A. 89, 2429-2433.
23. Roberts, B. L., Markland, W., Siranosian, K., Saxena, M. J., Guterman, S. K., & Ladner, R. C. (1992b) Protease Inhibitor Display M13 Phage: Selection of High Affinity Neutrophil Elastase Inhibitors, Gene 121, 9-15.
24. Royston, D. (1994) Aprotinin Therapy, Br. J. Anaesth. 73, 734-737.
25. Royston, D., Bidstrup, B. P., Taylor, K. M., & Sapsford, R. N. (1987) Effect of Aprotinin on Need for Blood Transfusion after Repeat Open-Heart Surgery, Lancet 2, 1289-1291.
26. Schechter, I., & Berger, A. (1968) On the Active Site of Proteases. III. Mapping the Active Site of Papain; Specific Peptide Inhibitors of Papain, Biochem. Biophys. Res. Commun. 32, 898-902.
27. Schmaier, A. H., Silverberg, M., Kaplan, A. P., & Colman, R. W. (1987) Contact Activation and Its Abnormalities, in Hemostasis and Thrombosis, 2nd ed. (Colman, R. W., Hirsh, J., Marder, V. J., & Salzman, E. W., Eds.) Chapter 2, J. B. Lippincott Company, Philadelphia, PA.
28. Scott, C. F., Wenzel, H. R., Tschesche, H. R., & Colman, R. W. (1987) Kinetics of Inhibition of Human Plasma Kallikrein by a Site-Specific Modified Inhibitor Arg15-Aprotinin: Evaluation Using a Microplate System and Comparison with Other Proteases, Blood 69, 1431-1436.
29. Wachtfogel, Y. T., Kucich, U., Hack, C. E., Gluszko, P., Niewiarowski, S., Colman, R. W., & Edmunds, L. H., Jr. (1993) Aprotinin Inhibits the Contact, Neutrophil, and Platelet Activation Systems During Simulated Extracorporeal Perfusion, J. Thorac. Cardiovasc. Surg. 106, 1-10.
30. Wachtfogel, Y. T., Hack, C. E., Nuijens, J. H., Kettner, C., Reilly, T. M., Knabb, R. M., Bischoff, R., Tschesche, H., Wenzel, H., Kucich, U., Edmunds, L. H., Jr., & Colman, R. W. (1995) Selective Kallikrein Inhibitors Alter Human Neutrophil Elastase Release During Extracorporeal Circulation, Am. J. Physiol. 268, H1352-H1357.
31. Wildevuur, Ch. R. H., Eijsman, L., Roozendaal, K. J., Harder, M. P., Chang, M., & van Oeveren, W. (1989) Platelet Preservation During Cardiopulmonary Bypass with Aprotinin, Eur. J. Cardio-Thorac. Surg. 3, 533-538.